A fresh wave of layoffs is sweeping across Northern California, with job cuts spanning the biotech, retail, agriculture and health care sectors — signaling mounting economic pressures in the region.

Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

The European Commission approved a tablet formulation of SMA treatment Evrysdi, a form aimed at giving patients more ...

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer ...

Genentech has announced plans to build a new biotechnology manufacturing plant in Holly Springs, North Carolina. The company, ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced two-year follow-up data from the Phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40% ...

A new facility is expected to support the metabolic medicines portfolio manufacture of Genentech and its parent company Roche. Credit: Michael Vi / Shutterstock. Genentech (San Francisco, CA) has ...

Lucentis was first approved for wet AMD by the FDA in 2006. Genentech is also developing DutaFabs – the next generation of bispecific antibodies designed for increased efficacy and durability ...